Basic Science ResearchEffects of Antiatherosclerosis in Carotid Artery by RNAi-Mediated Silencing of MCP-1 Expression
Introduction
Carotid artery stenosis is a major health threat that causes disability and death and is one of the leading causes of stroke.1 The mechanisms behind the development of atherosclerosis (AS) have been studied for half a century. Three main theories—namely, lipid infiltration, injury and repair, as well as thrombosis—have been put forward to explain atherogenesis. As experimental pathological studies go ahead, researchers have discovered that AS plaques show not only substantial accumulation of lipids but also infiltration of large numbers of inflammatory cells and secretion of inflammatory cytokines. In 1976, Ross and Glomset2 proposed the “injury-repair” theory to explain the formation of AS plaques. In the 1980s, he further proposed the “endothelial injury-repair” theory. In the 1990s, many scholars conducted numerous studies related to inflammatory factors, inflammatory markers, and AS plaques and thought that the inflammatory response was involved in the development and progression of AS plaques. In 1999, Ross explicitly proposed that AS was a kind of inflammatory proliferative disease. He believed that the formation of AS lesions resulted from the inflammatory fibroplasia of the artery after responding to arterial endothelial dysfunction caused by various major risk factors for this disease.3, 4, 5, 6, 7 The earliest pathomorphological changes in AS are characterized by the migration of monocytes/macrophages into the tunica intima and formation of subendothelial foam cells, followed by the migration (from tunica media to tunica intima) and hyperplasia of smooth muscle cells (SMCs). Currently, it is generally believed that monocyte chemotactic protein-1 (MCP-1)-mediated migration of monocytes into the arterial endothelium plays a key role in the early development of AS. MCP-1, as a member of the CC chemokine subfamily, is a glycoprotein with a molecular weight of 14 × 103. Studies show that vascular endothelial cells (VECs), vascular smooth muscle cells (VSMCs), mononuclear cells (MCs), macrophages, and fibroblasts express MCP-1. Through specifically acting upon peripheral blood MCs and attracting them to migrate into the subendothelium, MCP-1 plays an important role in the development and progression of AS.8, 9 Yla-Herttula et al.10 examined the expression of MCP-1 in rabbit and human AS lesions using Northern hybridization, in situ hybridization, and immunohistochemistry. They found that MCP-1 was positively expressed in rabbit AS arteries and Mφ-derived foam cells isolated from macrophage (Mφ)-rich AS lesions. In contrast, MCP-1 was negatively expressed in normal arteries and alveolar Mφ isolated from the same animal. In situ hybridization showed that MCP-1 mRNA was positively expressed in human and rabbit macrophage (Mφ)-rich AS lesions, while immunohistochemical analysis further proved that MCP-1 protein was expressed in MCP-1 mRNA-positive regions. In MCP-1-postive regions, ox-LDL was also positively expressed, which is consistent with the observation that ox-LDL could induce the in vitro expression of MCP-1 in VECs and VSMCs, suggesting that ox-LDL may be involved in the development of AS lesions by inducing the expression of MCP-1. Through studying the tunica intima of the carotid artery in patients undergoing endarterectomy and comparing that in subjects with normal arteries, Nelken et al.11 found that MCP-1 was positively stained in 16% of cells in AS carotid arteries, while the percentage of MCP-1-positive cells in normal arteries was <0.1%, proving that MCP-1 plays a role in the migration of monocytes into the wall of AS arteries. Schwartz et al.12 proved that MCP-1 was a strong monocyte chemotactic factor and could regulate the expression of relevant adhesion molecules in the vascular endothelium. After crossing CCR2 (a receptor of MCP-1)-deleted mice (CCR2-/-) with apolipoprotein E (apoE)-deleted mice (apoE-/-), Boring et al.13 discovered that CCR2 deletion could significantly reduce the incidence of AS. Similar studies also showed that in apoE-/- mice MCP-1 overexpression–induced acceleration of AS was associated with an increase in the number of macrophages in AS plaques.14, 15, 16 These discoveries indicate that MCP-1 plays an important role in the formation of AS, and it has been recognized as a new target for the prevention and treatment of AS.
Domestic and foreign scholars have made many attempts to explore the possibility using MCP-1 as a target for anti-inflammatory therapy.17, 18, 19, 20 Theoretically, many technologies, such as antisense technology, ribozyme technology, as well as peptide nucleic acid- and small-molecule peptide–based technologies, can be used to specifically inhibit the expression of target genes. However, these molecules or drugs are not easily designed. Moreover, it is possible to obtain the molecules that can specifically and efficiently suppress the expression of target genes only after many trial-and-error and screening tests are performed. The emergence of RNA interference (RNAi) technology provides a new clue for blocking the expression of MCP-1. As a new technology to inactivate target genes, RNAi has the advantages of easier design as well as higher inhibitory efficiency and specificity when compared with the above-mentioned technologies. Therefore, it has played important roles in studying gene function and screening drug targets in recent years.21, 22, 23, 24 At present, two strategies are mainly used in RNAi. One is to directly transfect small interfering (si) RNA (chemically synthesized or transcribed in vitro) into cells; the other is to introduce a vector system (plasmid or viral vectors) into cells, which can endogenously express siRNA.
In the present study, we constructed a eukaryotic expression vector of siRNA specific for MCP-1 and established a rabbit model of carotid AS. After liposome-mediated local transfection, we observed the impact of MCP-1 siRNA on the expression of MCP-1 in the artery and further analyzed the effect of MCP-1 siRNA on AS. The results will provide new clues for developing new interventional approaches for the prevention and treatment of this disease.
Section snippets
Vector Construction of MCP-1 siRNA
The pSilencer2.0-U6 vector was purchased from Ambion (Austin, TX). Escherichia coli strain DH-5α was provided by the Department of Biochemistry of our university (Guangzhou, P.R. China). Restriction endonucleases BamHI and HindIII, T4 DNA ligase, and ampicillin were purchased from Promega (Madison, WI). DNA molecular weight standard (λ-EcoT14 I digest) was purchased from Beijing Dingguo Biotechnology (Beijing, P.R. China). DNA purification and recovery kits were purchased from Beijing Jingshi
Construction of the psilencer2.0-U6-siMCP-1 plasmid
Since the eukaryotic expression vector psilencer2.0-U6 contains a multicloning site, restriction endonucleases BamHI and HindIII were used to linearize the plasmid. After the target fragment (MCP-1) was ligated into the linearized pcDNA3 plasmid using T4 DNA ligase, the recombinant eukaryotic expression plasmid psilencer2.0-U6-siMCP-1 was obtained (Fig. 1).
Identification of the recombinant plasmid by double digestion
Correct insertion of target fragments into expression vectors is key to the expression of exogenous genes. Since the linearized vector can
Discussion
Successful establishment of an AS animal model plays an important role in further investigation of the etiology, mechanism, prevention, and treatment of AS. Model reproduction with mechanical damage to endothelial cells in combination with high cholesterol feeding was characterized by simple manipulation, high success rate, short duration, and the similarity to human carotid AS, which has frequently been employed to establish a rabbit carotid AS model in recent years.26, 27, 28, 29, 30, 31
References (35)
Natural history of asymptomatic carotid artery stenosis
Rev Neurol (Paris)
(2008)- et al.
Atherosclerosis: the road ahead
Cell
(2001) - et al.
Inflammation and immune responses in atherosclerosis
Trends Immunol
(2002) - et al.
The role of chemokines in human cardiovascular pathology: enhanced biological insights
Atherosclerosis
(2002) - et al.
Activation of MCP-1 gene expression is mediated through multiple signaling pathways
Biochem Biophys Res Commun
(1993) - et al.
Monocyte chemoattractant protein-1 and atherosclerosis: is there room for an additional biomarker?
Clin Chim Acta
(2007) - et al.
Inhaled carbon monoxide inhibits intimal hyperplasia and provides added benefit with nitric oxide
J Vasc Surg
(2006) - et al.
Monocyte chemotactic protein-1 gene and protein expression in atherogenesis of hypercholesterolemic rabbits
Atherosclerosis
(1999) - et al.
ATP requirements and small interfering RNA structure in the RNA interference pathway
Cell
(2001) - et al.
The pathogenesis of atherosclerosis
N Engl J Med
(1976)
Inflammation in atherosclerosis
Nature
Atherosclerosis
Nature
MCP-1 induces activation of MAP-kinases ERK, JNK and p38 MAPK in human endothelial cells
Cardiovasc Res
Expression of monocyte chemocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerosis lesions
Proc Natl Acad Sci USA
Monocyte chemocyte chemoattractant protein 1 in human atheromatous plaques
Clin Invest
Atherosclerosis: potential targets for stabilization and regression
Circulation
Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis
Nature
Cited by (2)
Platelet-derived growth factor is associated with progression of symptomatic intracranial atherosclerotic stenosis
2021, Journal of Clinical Neurology (Korea)